TrialBlood2011

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

Bob Löwenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.